1578156-21-4

Basic information

• Product Name: 2-BROMO-3,4-DIFLUOROBENZALDEHYDE
• Synonyms: 2-bromo-3,4-difluorobenzaldehyde
• CAS NO: 1578156-21-4
• Molecular Formula: C₇H₃BrF₂O
• Molecular Weight: 220.9989264
• Mol File: 1578156-21-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BROMO-3,4-DIFLUOROBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-3,4-DIFLUOROBENZALDEHYDE(1578156-21-4)
• EPA Substance Registry System: 2-BROMO-3,4-DIFLUOROBENZALDEHYDE(1578156-21-4)

Safety Data

• Hazardous Substances Data: 1578156-21-4(Hazardous Substances Data)

Usage

General Description

2-Bromo-3,4-difluorobenzaldehyde is a chemical compound with the molecular formula C7H3BrF2O. It is a colorless to pale yellow liquid that is used in the synthesis of various pharmaceutical and agrochemical products. 2-BROMO-3,4-DIFLUOROBENZALDEHYDE is often used as a building block in the production of various pharmaceuticals, agrochemicals, and other organic compounds. It is known for its aromatic and aldehydic odor, and it is considered to be a highly reactive chemical that should be handled with care. 2-Bromo-3,4-difluorobenzaldehyde is also known to be a potential irritant to the eyes, skin, and respiratory system, and it should be used in accordance with proper safety precautions and handling procedures.

Upstream product

• 170108-05-1 2-bromo-3,4-difluorobenzoic acid 

Relevant articles and documents

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors

Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties compared to the first- and second-generation 4-H HAPs. X-ray crystallographic study of analogue 12 (HAP_R01) with Cp149 Y132A mutant hexamer clearly elucidated the role of C6 carboxyl group played for the increased binding affinity, which formed strong hydrogen bonding interactions with capsid protein and coordinated waters. The representative analogue 10 (HAP_R10) was extensively characterized in vitro (ADMET) and in vivo (mouse PK and PD) and subsequently selected for further development as oral anti-HBV infection agent.

6-AMINO ACID HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

The invention provides novel compounds having the general formula:, wherein R1, R2, R3, R4 and A are as described herein, compositions including the compounds and methods of using the compounds.